pentobarbital will decrease the level or impact of eplerenone by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Significance Unidentified.

Reserve concomitant prescribing of these drugs in people for whom other treatment choices are insufficient. Limit dosages and durations to the least required. Check intently for signs of respiratory despair and sedation.

pentobarbital will reduce the level or impact of ramelteon by impacting hepatic enzyme CYP2C9/10 metabolism. Minimal/Importance Unidentified.

pentobarbital will lessen the level or outcome of acalabrutinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.

pentobarbital will lessen the level or impact of ketoconazole by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Significance Not known.

pentobarbital will minimize the extent or outcome of armodafinil by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Importance Unidentified.

By clicking mail, you admit that you have permission to email the recipient using this information and facts.

pentobarbital will lessen the extent or influence of lumacaftor/ivacaftor by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

Contraindicated (1)pentobarbital will decrease the extent or influence of doravirine by influencing hepatic/intestinal enzyme CYP3A4 metabolism.

pentobarbital will decrease the level or outcome of pantoprazole by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Importance Unfamiliar.

pentobarbital will decrease the level or result of diazepam intranasal by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch. Strong or moderate CYP3A4 inducers may perhaps raise level of website diazepam elimination; consequently, efficacy of diazepam can be decreased.

pentobarbital will decrease the extent or result of cortisone by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on.

pentobarbital will decrease the level or result of buprenorphine subdermal implant by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Observe Closely. Monitor patients currently on buprenorphine subdermal implant who require recently-initiated cure with CYP3A4 inducer for indications and signs and symptoms of withdrawal.

pentobarbital will minimize the level or effect of lorlatinib by influencing hepatic/intestinal enzyme CYP3A4 metabolism.